Search results for "HFrEF"
showing 4 items of 4 documents
Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
2019
Visual Abstract
Effetti della Terapia con Sacubitril/Valsartan sulla Capacità di Esercizio dei pazienti con Scompenso Cardiaco a Frazione di Eiezione Ridotta (HFrEF)…
2021
Introduzione: La terapia con Sacubitril/Valsartan nei pazienti con scompenso cardiaco a frazione di eiezione ridotta (HFrEF) si è dimostrata superiore alla singola terapia con Enalapril nella riduzione del rischio di morte ed ospedalizzazione per scompenso cardiaco. Obiettivo del presente studio è stato quello di valutare, nei pazienti con HFrEF, gli effetti della terapia con sacubitril/valsartan sulla capacità di esercizio valutata mediante Test Cardiorespiratorio e l’eventuale correlazione con il grado di fibrosi miocardica valutata mediante Risonanza Magnetica Cardiaca (CMR). Metodi: E’ stato condotto uno studio osservazionale, prospettico. 134 pazienti ambulatoriali con HFrEF sono stati…
Echocardiography to estimate high filling pressure in patients with heart failure and reduced ejection fraction
2020
Aims: Echocardiographic assessment of left ventricular filling pressures is performed using a multi-parametric algorithm. Unselected sample of patients with heart failure with reduced ejection fraction (HFrEF) patients may demonstrate an indeterminate status of diastolic indices making interpretation challenging. We sought to test improvement in the diagnostic accuracy of standard and strain echocardiography of the left ventricle and left atrium (LA) to estimate a pulmonary capillary wedge pressure (PCWP) > 15 mmHg in patients with HFrEF. Methods and results: Out of 82 consecutive patients, 78 patients were included in the final analysis and right heat catheterization, and echocardiogram…
Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes
2020
Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…